GlassScriptPhysician profile
Glenn A Pfaff
NPI 1093810780
$349.12
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.40 · 2020: $224 · 2021: $64.87.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $42.79 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $37.18 | 2019-2020 | |
| Lilly USA, LLC | $34.94 | 2019-2020 | |
| Eisai INC. | $32.49 | 2020 | |
| Novo Nordisk INC | $31.81 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $30.11 | 2021 | |
| Glaxosmithkline, LLC. | $27.72 | 2020 | |
| Pfizer INC. | $26.04 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.72 | 2019-2020 | |
| Romark Laboratories, Lc | $19.44 | 2020 | |
| Esperion Therapeutics, INC. | $16.45 | 2020 | |
| Jazz Pharmaceuticals INC. | $12.56 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.87 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Pfaff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.